4/3/2012

The U.K. National Institute for Health and Clinical Excellence gave preliminary recommendation on Amgen's Xgeva, or denosumab, for treating bone metastasis in some cancer patients. Xgeva should be offered to the National Health Service at a discount, NICE said.

Full Story:
PMLive.com (U.K.)

Related Summaries